Market Price

7.95 

0.14 1.9%

as of Jul 13 '20

52 Week Range:

3.50 10.39


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19
Equity (BVPS) 372.09
643.01
1,869.14
0.52
0.69
0.67
1.95
2.07
2.77
3.29
growth rate 72.8% 190.7% -100.0% 32.7% -2.9% 191.0% 6.2% 33.8% 18.8%
Earnings BIT 1.23
6.75
10.25
18.00
21.52
22.60
31.00
42.90
51.10
58.00
growth rate 448.8% 51.9% 75.6% 19.5% 5.0% 37.2% 38.4% 19.1% 13.5%
Avg.PE 21.79
8.57
1.17
61.99
91.68
77.63
237.88
growth rate -60.7% -86.4% 5,198.3% 47.9% -15.3% 206.4%
ROA 4.67
17.51
16.88
17.82
17.66
2.17
3.07
0.83
4.86
0.60
growth rate 275.0% -3.6% 5.6% -0.9% -87.7% 41.5% -73.0% 485.5% -87.7%
ROE 15.32
53.15
32.84
28.03
27.65
4.20
6.12
1.57
9.15
1.32
growth rate 246.9% -38.2% -14.7% -1.4% -84.8% 45.7% -74.4% 482.8% -85.6%
ROIC 7.85
33.43
31.54
27.64
24.51
2.93
4.99
1.51
7.36
1.73
growth rate 325.9% -5.7% -12.4% -11.3% -88.1% 70.3% -69.7% 387.4% -76.5%
Cur. Ratio 0.56
0.96
1.22
1.34
1.33
0.66
0.69
0.65
1.35
0.95
growth rate 71.4% 27.1% 9.8% -0.8% -50.4% 4.6% -5.8% 107.7% -29.6%
Quick Ratio 0.48
0.89
1.02
0.79
1.10
0.47
0.54
0.51
1.02
0.67
growth rate 85.4% 14.6% -22.6% 39.2% -57.3% 14.9% -5.6% 100.0% -34.3%
Leverage 3.28
2.89
1.62
1.55
1.58
2.05
1.94
1.84
1.91
2.43
growth rate -11.9% -43.9% -4.3% 1.9% 29.8% -5.4% -5.2% 3.8% 27.2%
Balance Sheet Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19
Acct.Receivable 0.60
3.00
6.00
15.00
24.17
53.10
60.40
59.20
80.80
80.30
growth rate 400.0% 100.0% 150.0% 61.2% 119.7% 13.8% -2.0% 36.5% -0.6%
Acct.Payable 1.00
2.00
6.00
10.28
48.10
68.60
54.80
69.60
69.50
growth rate 100.0% 200.0% 71.3% 368.1% 42.6% -20.1% 27.0% -0.1%
Cur.Assets 3.70
15.00
23.00
37.00
51.43
110.00
112.20
111.40
153.50
231.30
growth rate 305.4% 53.3% 60.9% 39.0% 113.9% 2.0% -0.7% 37.8% 50.7%
Total Assets 19.50
30.00
48.00
79.00
104.86
419.10
459.90
459.50
667.10
1,066.10
growth rate 53.9% 60.0% 64.6% 32.7% 299.7% 9.7% -0.1% 45.2% 59.8%
Cash 2.20
10.00
5.00
11.00
21.79
27.80
27.80
27.80
36.30
83.50
growth rate 354.6% -50.0% 120.0% 98.1% 27.6% 0.0% 0.0% 30.6% 130.0%
Inventory 0.10
1.00
3.00
3.00
2.47
11.10
15.60
16.70
21.30
35.40
growth rate 900.0% 200.0% 0.0% -17.8% 350.1% 40.5% 7.1% 27.5% 66.2%
Cur.Liabilities 6.60
15.00
19.00
28.00
38.56
158.40
164.30
134.80
113.80
243.40
growth rate 127.3% 26.7% 47.4% 37.7% 310.8% 3.7% -18.0% -15.6% 113.9%
Liabilities 13.60
19.00
19.00
28.00
38.56
214.50
223.40
210.40
317.60
627.70
growth rate 39.7% 0.0% 47.4% 37.7% 456.3% 4.2% -5.8% 51.0% 97.6%
LT Debt 4.90
4.00
0.00
35.00
35.00
34.50
25.90
54.20
172.80
335.70
growth rate -18.4% -100.0% 0.0% -1.4% -24.9% 109.3% 218.8% 94.3%
Equity 6.00
10.30
29.90
51.00
66.31
204.60
236.50
249.10
349.50
438.40
growth rate 71.7% 190.3% 70.6% 30.0% 208.6% 15.6% 5.3% 40.3% 25.4%
Common Shares 83.00
83.00
76.00
82.00
85.00
90.00
114.00
116.00
121.00
132.00
growth rate 0.0% -8.4% 7.9% 3.7% 5.9% 26.7% 1.8% 4.3% 9.1%
Cash Flow Statement Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19
Capital Expenditures 1.40
4.00
0.40
1.00
0.64
0.20
1.30
1.40
1.20
2.00
growth rate 185.7% -90.0% 150.0% -35.9% -68.8% 550.0% 7.7% -14.3% 66.7%
Cash Dividends 1.10
0.00
0.80
0.50
2.48
2.60
4.10
4.90
6.30
7.70
growth rate -100.0% -37.5% 395.2% 5.0% 57.7% 19.5% 28.6% 22.2%
Cash From OA -0.93
13.00
4.00
18.00
19.04
13.10
42.10
46.10
47.60
68.30
growth rate 100.0% -69.2% 350.0% 5.8% -31.2% 221.4% 9.5% 3.3% 43.5%
FCF per Share 0.11
-0.03
-0.01
0.12
0.15
0.49
0.24
growth rate -100.0% 0.0% 100.0% 25.0% 226.7% -51.0%
Sale Purchase of Stock 132.40
132.40
0.30
0.50
growth rate 0.0% -99.8% 66.7%
FCF -2.00
8.00
-0.40
-1.00
-3.00
4.00
34.00
37.00
35.00
49.00
growth rate 100.0% -100.0% 0.0% 0.0% 100.0% 750.0% 8.8% -5.4% 40.0%
Income Statement Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19
Sales 21.30
35.00
82.00
123.00
126.64
184.40
339.90
302.30
381.20
456.90
growth rate 64.3% 134.3% 50.0% 3.0% 45.6% 84.3% -11.1% 26.1% 19.9%
Op.Income 1.20
4.00
7.00
18.00
21.52
22.60
31.00
42.90
51.10
58.00
growth rate 233.3% 75.0% 157.1% 19.5% 5.0% 37.2% 38.4% 19.1% 13.5%
IBT 1.20
6.80
10.30
14.50
21.28
8.30
15.90
14.10
35.90
12.30
growth rate 466.7% 51.5% 40.8% 46.8% -61.0% 91.6% -11.3% 154.6% -65.7%
Net Income 0.90
4.00
7.00
11.00
16.21
5.70
13.50
3.80
27.40
5.20
growth rate 344.4% 75.0% 57.1% 47.4% -64.8% 136.8% -71.9% 621.1% -81.0%
EPS 0.01
0.05
0.08
0.14
0.19
0.06
0.11
0.03
0.23
0.04
growth rate 400.0% 60.0% 75.0% 35.7% -68.4% 83.3% -72.7% 666.7% -82.6%
Gross Profit 6.80
16.00
29.00
35.00
41.20
53.70
100.70
122.80
140.10
182.30
growth rate 135.3% 81.3% 20.7% 17.7% 30.3% 87.5% 22.0% 14.1% 30.1%

Quarterly Statements

Item Name Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Earnings BIT 11.80
17.20
17.20
17.45
17.45
growth rate 45.8% 0.0% 1.5% 0.0%
Balance Sheet Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Acct.Receivable 96.70
80.30
80.30
134.80
134.80
growth rate -17.0% 0.0% 67.9% 0.0%
Acct.Payable 107.70
69.50
69.50
198.10
198.10
growth rate -35.5% 0.0% 185.0% 0.0%
Cur.Assets 177.70
231.30
231.30
227.80
227.80
growth rate 30.2% 0.0% -1.5% 0.0%
Total Assets 881.50
1,066.10
1,066.10
1,046.40
1,046.40
growth rate 20.9% 0.0% -1.9% 0.0%
Cash 55.10
83.50
83.50
39.80
39.80
growth rate 51.5% 0.0% -52.3% 0.0%
Inventory 25.80
35.40
35.40
52.00
52.00
growth rate 37.2% 0.0% 46.9% 0.0%
Cur.Liabilities 115.20
243.40
243.40
203.30
203.30
growth rate 111.3% 0.0% -16.5% 0.0%
Liabilities 445.10
627.70
627.70
605.60
605.60
growth rate 41.0% 0.0% -3.5% 0.0%
LT Debt 247.30
335.70
335.70
345.00
345.00
growth rate 35.8% 0.0% 2.8% 0.0%
Equity 436.40
438.40
438.40
440.80
440.80
growth rate 0.5% 0.0% 0.6% 0.0%
Common Shares 0.10
0.10
0.10
0.10
0.10
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Capital Expenditures 0.35
0.65
0.65
0.45
0.45
growth rate 85.7% 0.0% -30.8% 0.0%
Cash Dividends 2.55
1.30
1.30
3.15
3.15
growth rate -49.0% 0.0% 142.3% 0.0%
Cash From OA 12.55
21.60
21.60
-5.25
-5.25
growth rate 72.1% 0.0% -100.0% 0.0%
Sale Purchase of Stock
growth rate
FCF 12.20
20.95
20.95
-5.70
-5.70
growth rate 71.7% 0.0% -100.0% 0.0%
Income Statement Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Sales 104.45
124.00
124.00
121.85
121.85
growth rate 18.7% 0.0% -1.7% 0.0%
Op.Income 11.80
17.20
17.20
17.45
17.45
growth rate 45.8% 0.0% 1.5% 0.0%
IBT 6.45
-0.30
-0.30
12.40
12.40
growth rate -100.0% 0.0% 100.0% 0.0%
Net Income 4.95
-2.35
-2.35
9.40
9.40
growth rate -100.0% 0.0% 100.0% 0.0%
Gross Profit 40.00
51.15
51.15
54.05
54.05
growth rate 27.9% 0.0% 5.7% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (67.11)

YOY Growth Grade:

C (56.93)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 74.04 76.44 0.30
EPS / Growth 23.5% 0.10 21.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 39.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 21.0% 28.1% 28.1%
Future PE 0.30 43.52 43.52
Future EPS 0.70 1.24 1.24
Value Price
MOS %
0.05
-99.3%
13.32
67.6%
13.32
67.6%
MOS Price 0.03 6.66 6.66
IRT 13.94 11.59 11.59

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.